Remission as the critical outcome of depression treatment.
Major depressive disorder is currently the fourth largest contributor to the worldwide burden of disease. Direct and indirect costs associated with depression place a significant burden on the health care system and society. Despite the development of new antidepressant medications, the management of patients with depression remains a therapeutic challenge. Obtaining a response in antidepressant therapy-commonly defined in clinical trials as an improvement of >erotonergic and noradrenergic neurotransmission, will increase the likelihood of remission.
Thase
Michael E
ME
University of Pittsburgh Medical Center, Western Psychiatric Institute, Pittsburgh, Pennsylvania, USA.
Sloan
Diane M E
DM
Kornstein
Susan G
SG
D000928:Antidepressive Agents / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D006801:Humans; D011613:Psychotherapy; D016896:Treatment Outcome
D000928:Antidepressive Agents